Individual Investors

Subscribe to email updates

Subscribe now

Financial Professionals

Subscribe to email updates, or password protected financial professional-only content
email address/username
password

PPH
VanEck Vectors Pharmaceutical ETF

  • Fund Description

    VanEck Vectors® Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

  •  
      

    • Fund Ticker

      PPH
    • Exchange

      NASDAQ
    • Commencement

      12/20/2011
    • ETF Structure

      Physical
    • Administrator

      Van Eck Associates
    • Custodian

      Bank of New York Mellon
    • Index Ticker

      MVPPHTR
    • Index Rebalancing

      Quarterly
  •  
    as of 08/22/17

    • 30-Day SEC Yield1

      1.84%
    • Total Net Assets

      $267.2M
    • Number of Holdings

      26
    • Options

      Available
    • Gross Expense Ratio2

      0.41%
    • Net Expense Ratio/TER2

      0.35%
    • Distribution Frequency

      Quarterly
    • Next Distribution Date

      09/29/2017
  • Key Points

    Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
    Industry Leaders
    Index methodology favors the largest companies in the industry
    Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
     
  • Trading Information

    • Fund Ticker

      PPH
    • Index Total Return Ticker

      MVPPHTR
    • NAV

      PPHNV
    • Intraday NAV (IIV)4

      PPHIV
    • Shares Outstanding

      4,888,138
    • Estimated Cash

      PPHEU
    • Total Cash

      PPHTC
    • CUSIP

      92189F692
    • ISIN

      US92189F6925
    Source: Bloomberg
  • Fees and Expenses2

    • Management Fee

      0.35%
    • Other Expenses

      0.06%
    • Gross Expense Ratio

      0.41%
    • Fee Waivers and
      Expense Reimbursement

      -0.06%
    • Net Expense Ratio/TER2

      0.35%
    2 Expenses for PPH are capped contractually at 0.35% until at least February 1, 2018. Cap excludes certain expenses, such as interest.
  • Prices as of 08/22/17

    NAV/
    Last Price
    Volume
    30-Day Avg./
    Last Trading Day
    Daily Change
    NAV/
    Last Price
    YTD Change
    NAV/
    Last Price
    Premium/
    Discount
    Prem/Discount
    Distribution Charts
    NAV &
    Prem/Discount
    History
    NAV
    Chart
    PPH $54.66
    $54.63
    86,482
    18,033
    $0.59 / +1.10%
    $0.57 / +1.05%
    +5.92%
    +5.78%
    $-0.03
    -0.05%
  • View All IndicesView All ETFsPerformance History: Average Annual Total Returns* (%)

    1 MO3 MOYTD1 YR3 YR5 YR10 YRLIFE
    12/20/11
    PPH (NAV)-1.285.5712.37-4.280.5710.79--11.39
    PPH (Share Price)-1.305.6112.26-4.360.5710.77--11.58
    MVPPHTR (Index)-1.285.5612.01-4.270.6010.75--11.35
    Performance Differential (NAV - Index)0.000.010.36-0.01-0.030.04--0.04
    Quarter End as of 06/30/17
    1 MO3 MOYTD1 YR3 YR5 YR10 YRLIFE
    12/20/11
    PPH (NAV)2.987.9613.822.670.3711.47--11.84
    PPH (Share Price)2.988.0213.742.760.3611.48--12.03
    MVPPHTR (Index)3.017.9413.462.680.3911.44--11.79
    Performance Differential (NAV - Index)-0.030.020.36-0.01-0.020.03--0.05
  • Daily HoldingsTop 10 Holdings (%)  as of 07/31/17

    Total Holdings: 26
    Holding Name
    Ticker
    SharesMarket Value
    (US$)
    % of Net
    Assets
    Johnson & Johnson
    JNJ US
    185,973
    24,682,3378.62
    Novartis Ag
    NVS US
    223,033
    19,002,4126.64
    Pfizer Inc
    PFE US
    441,986
    14,656,2565.12
    Abbvie Inc
    ABBV US
    205,725
    14,382,2355.02
    Teva Pharmaceutical Industries Ltd
    TEVA US
    442,289
    14,228,4374.97
    Merck & Co Inc
    MRK US
    220,786
    14,103,8104.92
    Novo Nordisk A/S
    NVO US
    330,917
    14,030,8814.90
    Sanofi
    SNY US
    292,582
    13,856,6844.84
    Bristol-Myers Squibb Co
    BMY US
    242,137
    13,777,5954.81
    Eli Lilly & Co
    LLY US
    160,337
    13,253,4564.63
    Top 10 Total (%)54.47
    These are not recommendations to buy or to sell any security. Securities and holdings may vary.
  • Country Weightings (%) as of 07/31/17

    • Country

      % of Net Assets
    • UNITED STATES

      69.24
    • UNITED KINGDOM

      9.68
    • SWITZERLAND

      6.64
    • ISRAEL

      4.97
    • DENMARK

      4.90
    • FRANCE

      4.84
    • Other/Cash

      -0.26
  • Sector Weightings (%) as of 07/31/17

    • Sector

      % of Net Assets
    • Health Care

      100.3
    • Other/Cash

      -0.3
  • Important Disclosure

    VanEck only serves professional clients in countries where the funds are registered or where funds can be sold in accordance with local private placement rules.

    130-Day SEC Yield is a standard yield calculation developed by the Securities and Exchange Commission that allows for fairer comparisons among funds. It is based on the most recent 30-day period. This yield figure reflects the interest earned during the period after deducting the fund's expenses for the period. It does not reflect the yield an investor would have received if they had held the fund over the last twelve months assuming the most recent NAV. Distributions may vary from time to time. In the absence of temporary expense waivers or reimbursements, the 30-Day SEC Yield for VanEck Vectors Pharmaceutical ETF would have been 1.79% on 08/22/2017.

    2Fees & Expenses for PPH are capped contractually at 0.35% until at least February 1, 2018. Cap excludes certain expenses, such as interest. TER, or Total Expense Ratio, is also referred to as "Net Expense Ratio".

    3Morningstar Ratings : ©Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. 

    4IIV is an abbreviation for the intraday indicative value of an ETF's Shares (and is also known as the Indicative Optimized Portfolio Value or IOPV), and is disseminated every 15 seconds during regular trading hours. The IIV is based on the current market value of the securities and/or cash required to be deposited in exchange for a Creation Unit. The IIV does not necessarily reflect the precise composition of the current portfolio of securities held by the Fund at a particular point in time or the best possible valuation of the current portfolio. Therefore, the IIV should not be viewed as a "real-time" update of the Fund's NAV, which is computed only once a day. The Fund is not involved in, or responsible for, the calculation or dissemination of the IIV and makes no warranty as to its accuracy.

    6The S&P 500® Index consists of 500 widely held common stocks covering industrial, utility, financial and transportation sector; as an Index, it is unmanaged and is not a security in which investments can be made.

    For each fund with at least a three-year history, Morningstar calculates a Morningstar Rating based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a fund's monthly performance (including the effects of sales charges, loads, and redemption fees), placing more emphasis on downward variations and rewarding consistent performance. The top 10% of funds in each category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars and the bottom 10% receive 1 star. (Each share class is counted as a fraction of one fund within this scale and rated separately, which may cause slight variations in the distribution percentages.) The Overall Morningstar Rating for a fund is derived from a weighted average of the performance figures associated with its three-, five- and ten-year (if applicable) Morningstar Rating metrics.

    Price/Book Ratio is the price of a security divided by the book value per share of the security. Price/Earnings Ratio is the price of a security divided by the earnings per share of the security.

    An investment in the Fund may be subject to risks which include, among others, investing in the pharmaceutical and health care sectors, equity securities, depositary receipts, special risk considerations of investing in European issuers, foreign securities, medium-capitalization companies, issuer-specific changes, market, operational, index tracking, authorized participant concentration, no guarantee of active trading market, trading issues, replication management, fund shares trading, premium/discount risk and liquidity of fund shares, non-diversified, and concentration risks, all of which may adversely affect the Fund. Foreign investments are subject to risks, which include changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations, and changes in currency exchange rates which may negatively impact the Fund's returns. Medium-capitalization companies may be subject to elevated risks. The Fund's assets may be concentrated in a particular sector and may be subject to more risk than investments in a diverse group of sectors.

    MVIS US Listed Pharmaceutical 25 Index is the exclusive property of MV Index Solutions GmbH (a wholly owned subsidiary of the Adviser), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MV Index Solutions GmbH, Solactive AG has no obligation to point out errors in the Index to third parties. The VanEck Vectors Pharmaceutical ETF is not sponsored, endorsed, sold or promoted by MV Index Solutions GmbH and MV Index Solutions GmbH makes no representation regarding the advisability of investing in the Fund.

    Index returns are not Fund returns and do not reflect any management fees or brokerage expenses. Investors can not invest directly in the Index. Returns for actual Fund investors may differ from what is shown because of differences in timing, the amount invested and fees and expenses. Index returns assume that dividends have been reinvested.

    The "Net Asset Value" (NAV) of a VanEck Vectors Exchange Traded Fund (ETF) is determined at the close of each business day, and represents the dollar value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF's intraday trading value. VanEck Vectors ETF investors should not expect to buy or sell shares at NAV.

    Fund shares are not individually redeemable and will be issued and redeemed at their NAV only through certain authorized broker-dealers in large, specified blocks of shares called "creation units" and otherwise can be bought and sold only through exchange trading. Shares may trade at a premium or discount to their NAV in the secondary market. You will incur brokerage expenses when trading Fund shares in the secondary market. Past performance is no guarantee of future results. Returns for actual Fund investments may differ from what is shown because of differences in timing, the amount invested, and fees and expenses.

    Investing involves substantial risk and high volatility, including possible loss of principal. An investor should consider the investment objective, risks, charges and expenses of the Fund carefully before investing. To obtain a prospectus and summary prospectus , which contains this and other information, call 800.826.2333 or visit vaneck.com/etfs . Please read the prospectus and summary prospectus carefully before investing.

    This content is published in the United States for residents of specified countries. Investors are subject to securities and tax regulations within their applicable jurisdictions that are not addressed on this content. Nothing in this content should be considered a solicitation to buy or an offer to sell shares of any investment in any jurisdiction where the offer or solicitation would be unlawful under the securities laws of such jurisdiction, nor is it intended as investment, tax, financial, or legal advice. Investors should seek such professional advice for their particular situation and jurisdiction.